about
Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradationDifferential regulation of cell motility and invasion by FAKHuman embryonic stem cells derived from embryos at different stages of development share similar transcription profilesReduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient micev-Src SH3-enhanced interaction with focal adhesion kinase at beta 1 integrin-containing invadopodia promotes cell invasion.FAK induces expression of Prx1 to promote tenascin-C-dependent fibroblast migration.Integrin alpha4beta1 promotes focal adhesion kinase-independent cell motility via alpha4 cytoplasmic domain-specific activation of c-Src.Self-organization of the human embryo in the absence of maternal tissues.Promises and challenges of the first clinical-grade induced pluripotent stem cell bank.Cost-effective master cell bank validation of multiple clinical-grade human pluripotent stem cell lines from a single donor3D In vitro model of a functional epidermal permeability barrier from human embryonic stem cells and induced pluripotent stem cells.Trophoblast L-selectin-mediated adhesion at the maternal-fetal interface.Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment.Safety paradigm: genetic evaluation of therapeutic grade human embryonic stem cellsEstablishment of cell lines from mouse embryos with early embryonic lethality.Conversion of mechanical force into TGF-β-mediated biochemical signals.Three Huntington's Disease Specific Mutation-Carrying Human Embryonic Stem Cell Lines Have Stable Number of CAG Repeats upon In Vitro Differentiation into Cardiomyocytes.Control of motile and invasive cell phenotypes by focal adhesion kinase.sPLA2 and the epidermal barrier.GROα regulates human embryonic stem cell self-renewal or adoption of a neuronal fate.Generation of KCL032 clinical grade human embryonic stem cell lineGeneration of KCL016 research grade human embryonic stem cell line carrying a mutation in VHL gene.Generation of KCL038 clinical grade human embryonic stem cell lineGeneration of KCL037 clinical grade human embryonic stem cell line.Generation of KCL039 clinical grade human embryonic stem cell line.Generation of KCL040 clinical grade human embryonic stem cell line.Generation of KCL021 research grade human embryonic stem cell line carrying a ΔF508 mutation in the CFTR geneGeneration of KCL034 clinical grade human embryonic stem cell line.Generation of KCL029 research grade human embryonic stem cell line carrying a mutation in WAS gene.Generation of KCL031 clinical grade human embryonic stem cell line.Generation of KCL035 research grade human embryonic stem cell line carrying a mutation in HBB gene.Generation of KCL024 research grade human embryonic stem cell line carrying a mutation in NF1 geneGeneration of KCL026 research grade human embryonic stem cell line carrying a mutation in SMN1 gene.Generation of KCL025 research grade human embryonic stem cell line carrying a mutation in NF1 gene.Generation of KCL012 research grade human embryonic stem cell line carrying a mutation in the HTT geneGeneration of KCL027 research grade human embryonic stem cell line carrying a mutation in the HTT geneGeneration of KCL028 research grade human embryonic stem cell line carrying a mutation in the HTT geneGeneration of KCL013 research grade human embryonic stem cell line carrying a mutation in the HTT gene.Generation of KCL033 clinical grade human embryonic stem cell lineGeneration of KCL018 research grade human embryonic stem cell line carrying a mutation in the DMPK gene
P50
Q24307387-344DEFD8-6289-46DB-9489-93886C3302D1Q24673170-75F52F48-B055-4961-A42F-9D8085CECD90Q28743560-95220F4B-23CF-454C-9094-D78C5AAC02C3Q29617498-A53004C2-5762-439C-A6CC-1D20A8519DC6Q30167613-781FBB79-727D-4F16-82FC-F4E42EEB1CA3Q30441881-4DE45DF7-4F52-4071-B194-0ADF28A58EFBQ30476291-4B9AB992-BADB-4E25-97F6-9AB13F5D62DEQ30818621-60691FAA-3D4D-4E63-91D1-CA3049972949Q33455454-EF92F8BE-B384-4B15-91EF-60E55F84C497Q33456790-0748CC95-F38E-432B-B610-BA4290D731E0Q33730154-7AB01DFC-BD15-4BFF-9C89-04DA514720FDQ34171141-2815BBD5-8B36-4C3A-9C94-29B7EA628409Q34313297-C846FA22-972D-44F5-A1F3-29482576D103Q34333314-993AC8F8-E30B-47BD-9088-0AAA89AE9CADQ34674503-F65B5351-7108-410F-A4F5-846D44C6F5D9Q35055426-4246828F-9C62-49C6-B842-002D3772086EQ35628135-514E092A-B284-41DC-9711-54B1D3C45273Q35832728-B77F35B3-06D7-4737-B9ED-6B7A0E4D4A2EQ35994859-E6E87149-3DE2-4633-B65C-D850929299A0Q36018997-33AE235B-805D-40E8-885D-74103416821DQ36061836-09352190-FB1C-4366-82FB-AA5E3178BF1EQ36061840-A3D7EF0E-E00F-49DA-97C0-13FF288D3F5FQ36061848-C3CE046A-F49D-46E4-B6C5-DAE3F2A03485Q36061858-BAAE8DE2-6653-4920-97D3-3632336B7251Q36061862-75C39497-A765-4932-852B-A9B2B9A6CB6CQ36061867-3C2267D4-576C-468C-ADCB-8CF5CBA0F1DDQ36061870-0E563F41-338A-4A50-AD38-6D18F9272DC8Q36061875-571E748F-B0C2-496F-952E-364AE04336F6Q36061878-B60DA5BA-B2A2-417F-8854-35A39FD387DDQ36061881-F548D73C-B113-4F2B-872F-F7A8D4E460EFQ36061888-B216CB76-2137-47B1-8853-B6C50FCF9B44Q36061892-7D21D51D-34D0-4E58-86E3-C39595605240Q36061896-D98726B6-5C39-4779-AAF0-0EA22A737B64Q36061900-A77E3CC2-DEA6-490A-94C2-59817E132BA6Q36061905-5C01E007-4213-4423-A004-42164116FA7FQ36061913-6357B235-DDC2-4EAF-BAE3-4F2133911D7AQ36061916-A5FDE7C1-027D-4F9E-B15B-6FC01CEEE6CAQ36061921-C1E09DAE-1A3F-40DC-9BC8-92D0200D76FBQ36061925-9C5DE372-F836-4729-836E-4291CE4D09C6Q36061929-FE761F09-690E-4433-A158-4D25256765A1
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dusko Ilic
@ast
Dusko Ilic
@en
Dusko Ilic
@es
Dusko Ilic
@nl
type
label
Dusko Ilic
@ast
Dusko Ilic
@en
Dusko Ilic
@es
Dusko Ilic
@nl
prefLabel
Dusko Ilic
@ast
Dusko Ilic
@en
Dusko Ilic
@es
Dusko Ilic
@nl
P106
P108
P1153
7005535777
P31
P496
0000-0003-1647-0026